Specific demographic, clinical, and financial characteristics are associated with glucagon-like peptide 1 (GLP-1) receptor ...

WATERTOWN, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: VIGL), a clinical-stage biotechnology company committed to ...

A recent study in the Journal of Clinical Medicine found that oral semaglutide significantly improves glycemic control and ...

NORWOOD, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that Yuval ...

Popular weight loss drugs like Wegovy and Ozempic have changed the way many Americans are eating and as people taking these ...

Live webcasts of the fireside chats will be available on the investor relations page of te Terns Pharmaceuticals website at http://ir.ternspharma.com. A replay of the webcasts will be archived on ...

E-cigarettes were introduced in the early 2000s as a way for smokers to manage their nicotine addiction without exposing ...

Patients who received CT-388 had an average placebo-adjusted weight loss of 18.8%. CT-388 is well tolerated with only mild to ...

Zealand Pharma’s GLP-1/GLP-2 receptor dual agonist may have only managed at best an average 4.3% reduction in weight loss ...

Tokyo, Japan and Cambridge, UK, 30 May 2024 - Nxera Pharma ("the Company" or "Nxera"; TSE: 4565) today announced that it expects to receive $4.6 million in milestone payments from Centessa Pharmaceuti ...

Merck & Co. agrees to acquire Eyebiotech (EyeBio) for up to $3 billion, a deal that will return the buyer to the eye drug ...

Altimmune is developing pemvidutide, a dual agonist of GLP-1 and glucagon receptors, with promising phase 2 data already seen ...